Eli Lilly is recommending low-dose Zepbound and Foundayo as options for weight loss maintenance after patients have achieved initial reduction. The recommendations are based on new clinical trial data showing that reduced dosing maintains safety and efficacy while potentially lowering treatment…
Eli Lilly has proposed that decreasing the dose of its obesity injection Zepbound can provide a safe and effective way to sustain weight loss over time. New data from clinical trials supports this approach, suggesting that it may be more affordable for patients compared to standard dosing. The company specifically positions this method for individuals who have already achieved significant weight reduction and are looking for ways to keep the weight off.
Lilly has also identified Foundayo as a suitable choice for ongoing weight management. Both Zepbound, at a lower dose, and Foundayo are intended to help people maintain their weight loss without continuing on full-dose therapy. This dual-option strategy draws directly from recent trial evidence, according to the company.
The findings that support these recommendations come from a trial that tested dose reduction with Zepbound. Results from this study indicate that the lower dose maintains efficacy for weight control, meaning patients can still keep the weight off even with a smaller amount of the medication. Safety remains consistent at this reduced dosing level, according to the data presented by Lilly.
Researchers evaluated how reduced Zepbound dosing performs over an extended period. The trial provided evidence for its role in long-term weight maintenance, and Lilly references this work to endorse the low-dose option. The company also points to Foundayo as a viable maintenance tool, though specific trial data for that medication was not detailed in the announcement.
A lower dose of Zepbound could help lower treatment costs for patients, which may make long-term use more practical. The company states that this reduced dose delivers the same benefits for preserving weight loss as higher amounts. This makes the approach suitable for extended use without sacrificing results.
Foundayo joins low-dose Zepbound as one of Lilly's recommended maintenance tools. Both options address the challenge of sustaining obesity treatment results after initial weight loss is achieved. The new data validates their potential for helping patients maintain their progress over time.
Eli Lilly highlights low-dose Zepbound and Foundayo specifically for weight loss upkeep. The company bases this recommendation on trial outcomes that demonstrate both safety and effectiveness. Patients may find these approaches more accessible for long-term use, particularly if cost or tolerability with full doses are concerns. Lilly has not provided specific pricing details for the reduced dosing regimen but emphasizes that the potential for lower costs is a key advantage.
Peptides referenced: Tirzepatide.
Related reading: AstraZeneca $800M Drug Misses Phase 3 Goal on Immunogenicity, Study: Orforglipron Maintains Most Weight Loss from Injectables, Adults Retain Most Weight Loss After Switching to Foundayo, Oral Orforglipron Effective for Obese Older Adults.